Evidence map›Paper›PMID 37951584›Full record

Trial reportEuropean journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery2024

Octreotide improves human lymphatic fluid transport a translational trial.

Thomas Holm-Weber, Frederik Skov, Sheyanth Mohanakumar, Lene Thorup, Troels Riis, Mikkel Bring Christensen, David Peick Sonne, Per Bo Jensen, Donna Briggs Bødtkjer, Vibeke Elisabeth Hjortdal

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Practical therapeutic options for postoperative chylothorax.Journal of cardiothoracic surgery · 2026
    Article
  2. Dietary interventionsWorld journal of transplantation · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Thomas Holm-WeberDepartment of Thoracic Surgery, Rigshospitalet, Copenhagen, Denmark.ORCID 0000-0001-8683-3254
Frederik SkovDepartment of Biomedicine, Aarhus University, Aarhus, Denmark.
Sheyanth MohanakumarDepartment of Radiology, Aarhus University Hospital, Denmark.ORCID 0000-0002-4368-2246
Lene ThorupDepartment of Thoracic Surgery, Rigshospitalet, Copenhagen, Denmark.
Troels RiisDepartment of Clinical Pharmacology, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark.ORCID 0000-0002-5208-8353
Mikkel Bring ChristensenDepartment of Clinical Pharmacology, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark.ORCID 0000-0002-8774-1797
David Peick SonneDepartment of Clinical Pharmacology, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark.ORCID 0000-0002-4898-2256
Per Bo JensenDepartment of Biochemistry, Bispebjerg Hospital, Copenhagen, Denmark.ORCID 0000-0002-2277-1135
Donna Briggs BødtkjerDepartment of Biomedicine, Aarhus University, Aarhus, Denmark.ORCID 0000-0003-1736-3484
Vibeke Elisabeth HjortdalDepartment of Thoracic Surgery, Rigshospitalet, Copenhagen, Denmark.ORCID 0000-0002-8047-0015
Rigshospitalet · DKAarhus University · DKUniversity of Copenhagen · DKAarhus University Hospital · DKBispebjerg Hospital · DKFrederiksberg Hospital · DK

Funding

Aarhus University Research FoundationDanish Research Council DFF-4183-00333
6 · The paper itself

Abstract

objectivesChylothorax is a complex condition and many different pharmacological agents have been tried as treatment. Octreotide is used off-label to treat chylothorax, but the efficacy of octreotide remains unclear. A decrease in lymph production is suggested as the mechanism. In this cross-over study, we explore the direct effect of octreotide on human lymphatic drainage.

methodsPre-clinical: the effect of octreotide on force generation was assessed during acute and prolonged drug incubation on human lymphatic vessels mounted in a myograph. Clinical: in a double-blinded, randomized, cross-over trial including 16 healthy adults, we administered either octreotide or saline as an intravenous infusion for 2.5 h. Near-infrared fluorescence imaging was used to examine spontaneous lymphatic contractions and lymph pressure in peripheral lymphatic vessels and plethysmography was performed to assess the capillary filtration rate, capillary filtration coefficient and isovolumetric pressures of the lower leg.

resultsPre-clinical: human thoracic duct (n = 12) contraction rate was concentration-dependently stimulated by octreotide with a maximum effect at 10 and 100 nmol/l in the myograph chamber. Clinical: spontaneous lymphatic contractions and lymph pressure evaluated by near-infrared fluorescence did not differ between octreotide or placebo (P = 0.36). Plethysmography revealed similar capillary filtration coefficients (P = 0.057), but almost a doubling of the isovolumetric pressures (P = 0.005) during octreotide infusion.

conclusionsOctreotide stimulated lymphatic contractility in the pre-clinical setup but did not affect the spontaneous lymphatic contractions or lymph pressure in healthy individuals. Plethysmography revealed a doubling in the isovolumetric pressure. These results suggest that octreotide increases lymphatic drainage capacity in situations with high lymphatic afterload.

Indexed as

ChylothoraxLymphatic VesselsAdultCross-Over StudiesGastrointestinal AgentsHumansOctreotideGastrointestinal AgentsOctreotideChylothoraxClinical studyLymphaticNear-infrared fluorescence imagingOctreotideRandomized cross-over study

Identifiers

PMID37951584
PMCPMC10832356
OpenAlexW4388599335

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.